Schizophrenia is a life-shortening disease and life expectancy in patients may be 15–20
years shorter than in the general population, with increasing longevity gap over time …

Aim: We conducted a matched-cohort study to assess mortality in schizophrenia and the
relationship of mortality with comorbid somatic conditions and suicide attempts. Method: A …

Introduction Patients with schizophrenia have an elevated mortality risk compared to the
general population, with cardiovascular-related deaths being the leading cause. The role of …

Importance Although adults with schizophrenia have a significantly increased risk of
premature mortality, sample size limitations of previous research have hindered the …

Antipsychotics are effective in preventing relapses of schizophrenia, but it is generally
believed that their long‐term use is harmful for patients' physical well‐being. However, there …

Affecting up to 1% of the global population, schizophrenia is a chronic, disabling psychiatric
disorder that has profound effects on patients, families, and caretakers due to its tremendous …

An important step to improve outcomes for patients with schizophrenia is to understand
treatment patterns in routine practice. The aim of the current study was to describe the long …

Compared to the general population, people with schizophrenia are at risk of dying
prematurely due to suicide and due to different somatic illnesses. The potential role of …

AimsCardiometabolic diseases are responsible for the majority of premature deaths in
people with schizophrenia. This study aimed to quantify the fatal burden of ischaemic heart …

Purpose Cardiovascular and metabolic adverse events are costly to treat, and their
incidence is increased amongst people with schizophrenia, with different rates observed for …